This study focused on evaluating the binding interactions of undoped ZnO and Ni/Cu-ZnO NPs with potential anticancer targets, Estrogen receptor alpha (ERα) is the primary clinical biomarker used for subtyping breast tumors. Here, ESR1 is linked to breast neoplasm.